What Is a CDA in Clinical Trials? CDA, NDA, and CTA Explained

A CDA is the first piece of paper you'll usually sign when a sponsor wants to talk to you about a study. It stands for Confidential Disclosure Agreement — you'll also see Confidentiality Disclosure Agreement — and it's the same idea as an NDA. There are a few agreements that show up as you become a site, so here's what each one is and which one actually matters.

CDA and NDA are the same thing

A CDA — written out as either Confidential Disclosure Agreement or Confidentiality Disclosure Agreement, both are used — and an NDA (Non-Disclosure Agreement) are, for all practical purposes, the same document wearing two different names. In clinical research you'll hear CDA more often; the same document also shows up as a "confidentiality agreement" with no acronym at all. Either way, it's a promise: if the sponsor shares confidential information with you, you'll keep it confidential and only use it to evaluate the study.

Why you sign it first

Before a sponsor sends you a full protocol, they need to protect it. The protocol has proprietary details about the drug and the study design that they don't want floating around. So the CDA comes early, often before you've even seen enough to decide whether you want the study. Signing it doesn't commit you to running the trial. It only commits you to confidentiality. It unlocks the conversation, nothing more.

What a CDA covers

Most CDAs are short and cover the same ground:

• What counts as confidential information
• That you'll only use it to assess the study
• How long the obligation lasts
• What you do with the materials if you decide not to proceed

For a small site, the majority of CDAs are standard boilerplate. Read it anyway, and get legal help for anything that looks unusual or one-sided.

One-way or mutual — and why it matters to a site

CDAs come in two shapes. A one-way CDA protects only the sponsor's information. A mutual CDA protects both sides — and during feasibility you disclose real things about your practice too: aggregate patient counts, staffing, capabilities, sometimes your track record on other studies. If the version in front of you is one-way and you'll be sharing that kind of detail, asking for a mutual CDA is a routine request.

Who actually signs it

The CDA binds a legal entity, so the signature usually belongs to whoever can bind your practice or site — an owner, officer, or authorized signatory — not automatically the PI. At a physician-owned practice those may be the same person wearing two hats, but sign as the entity, not as an individual investigator, so the obligation sits with the business rather than one person. If an institution or network owns your site, their contracts office likely has to sign, and looping them in on day one is what keeps a two-day turnaround from becoming three weeks.

Red flags worth slowing down for

Most CDAs are routine. These clauses are the exceptions worth a closer read, or counsel:

• A definition of "confidential information" so broad it covers everything you ever learn from anyone
• Obligations with no end date, where a defined term is the norm
• Anything resembling a non-compete — restrictions on running other sponsors' studies
• One-way protection when you'll be disclosing your own site information
• Terms that claim ownership of anything you develop or observe, which belongs in a CTA negotiation, not a confidentiality agreement

None of these is necessarily a deal-breaker, but each is a reason to ask a question before signing rather than after.

The CTA is the one that matters

Here's the thing to remember: the CDA is not the deal. The Clinical Trial Agreement, or CTA, is the real contract, and it comes later, after feasibility. The CTA covers the budget, payment terms, each side's obligations, indemnification, publication rights, and intellectual property. This is the document worth negotiating and worth having a lawyer review. The payment terms and holdbacks that shape your cash flow live here, which is covered in how much clinical trial sites get paid.

The rough order

1. Sign the CDA (confidentiality)
2. See the full protocol
3. Go through feasibility
4. Negotiate the CTA and budget
5. Get IRB approval and start up

The full walkthrough is in how to become a clinical trial site.

What to watch for

• Read the CDA even when it's routine. Occasionally the terms are broader than they should be.
• Keep track of what you've signed and with whom. Once you're talking to several sponsors, this piles up fast.
• Turn it around quickly. The CDA is the first speed test a sponsor gives you — it gates the feasibility questionnaire that usually follows, and a slow signature reads as a slow site.
• Save your real scrutiny for the CTA. That's where the money and the risk are.

Common questions

What does CDA stand for in clinical trials? Confidential Disclosure Agreement (you'll also see "Confidentiality Disclosure Agreement"). It's the clinical-research name for what most industries call an NDA.

Is a CDA legally binding? Yes — it's a contract, and breaching it has real consequences. That's exactly why it should be signed by someone authorized to bind your practice, and why it deserves a read even when it looks routine.

Do we need a lawyer to sign a CDA? For a standard, mutual, time-limited CDA, many sites review it themselves and reserve counsel for anything on the red-flag list above. For the CTA that comes later, use a lawyer — that's where the money, indemnification, and IP live.

Can we negotiate a CDA? Yes, and reasonable asks — making it mutual, adding a defined term, narrowing an overbroad definition — are common and rarely slow things down.

Want to see which sponsors are worth starting that conversation with? Start a free TrialWave trial, no card required.

---

This is general information, not legal advice. Have qualified counsel review any agreement before you sign it.